(Q51000664)

English

Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.

scientific article published on 28 July 2015

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26218930

Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26218930

metastatic melanoma

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26218930

Richard Scolyer

10

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26218930

Richard F. Kefford

11

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26218930

Georgina V. Long

12

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26218930

Alexander M Menzies

object named as

Alexander M Menzies

1

0 references

John F Thompson

7

object named as

John F Thompson

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26218930

James S Wilmott

2

object named as

James S Wilmott

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26218930

5

object named as

Megan Lyle

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26218930

9

object named as

Matteo S Carlino

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26218930

author name string

Martin Drummond

3

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26218930

Matthew M K Chan

6

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26218930

Alex Guminski

8

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26218930

language of work or name

0 references

publication date

28 July 2015

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26218930

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26218930

121

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26218930

21

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26218930

3826-3835

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26218930

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

Improved overall survival in melanoma with combined dabrafenib and trametinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

Final version of 2009 AJCC melanoma staging and classification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

Determinants of outcome in melanoma patients with cerebral metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

Importance of glycolysis and oxidative phosphorylation in advanced melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

Age and gender are significant independent predictors of survival in primary cutaneous melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

21 January 2018

Prognostic factors for survival in melanoma patients with brain metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

7 January 2021

based on heuristic

inferred from DOI database lookup

Gender Disparities in Patients With Melanoma: Breaking the Glass Ceiling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29586

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.29586

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26218930

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/26218930

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51000664&oldid=1857990666"